HomePrincipal Investigator
Principal Investigator
Principal Investigator
Name：Yinxiong Li
Professional：Principle Investigator
Email：li_yinxiong@gibh.ac.cn
Address：
Study/Work Experience
 

2012.05–now

Guanzhou Institutes of Biosciences and Heath, Chinese Academy of Sciences/Principal Investigator

2011.05 – 2012.05

SMT Inc./Chief Technology Officer and Vice President

2010.05 – 2011.05

Medical University of South Carolina/Associate Professor

2001.03 – 2010.05

Duke University Medical Center/Assistant Professor (Tenure Track)

1993.03 – 2001.03

Medical College of Georgia/postdoctoral fellow

1992.09 – 1993.03

Vanderbilt University Medical Center/ postdoctoral fellow

1991.11 – 1992.09

Chinese Academy of Medicines Sciences/ Assistant Professor

1987.09 – 1991.11

Peking Union Medical College/Ph.D

1985.09 – 1987.09

Chinese Academy of Medicines Sciences/Research assistant

1980.09 – 1985.08

Hunan Medical College/Bachelor

Research Areas
Dr Li’s group are focusing on stem cell biology and liver diseases intervention, including hepatic stem cell differentiation, expansion, transplantation mediating fibrosis repair and parenchymal tissue regeneration; pathological biomarker screening; Drug discovery based on key targets for insulin resistant, metabolic syndrome, type II diabetes and cardiovascular diseases
Academic Performance
Dr. Li is a National Distinguished Expert recruited by Chinese Central Government. He currently is the Chairman of Academic Council Committee in GIBH, Chief Scientist for stem cell mediated repairing cirrhosis research of the National 973 Program. in stem cell  hepatic differentiation, progenitor amplification and stemness  maintenance and repair of hepatic fibrosis has breakthrough progress. He has Published more than 40 papers on international journal, including 1 paper as corresponding author published on the journal of Science, another paper published on Lab Investigation, was named the best cell molecular biology and developmental focus paper by Nature. His inventions were granted several international patents covering these fields of DNA protection from mutation, tissue regeneration, gene silence and single cell RNA amplification. One product driven from Dr. Li’s dsRNA Patent that enter and finished clinical trial phase I b, first-in-human safety and tolerability study of an RNAi-based therapy, NUC B1000, among patients with mild to moderate chronic HBV.

 

Representative Papers
 

1. Liu Y, Wu F,……, Li Y-X*.Generation of WAe001-A-15, a human embryonic stem cell line with miR-122 doxycycline-inducible expression. Stem Cell Res. 2018 May;29:84-87

2. Xu G, Guo D,……, Pan T, Li Y-X*. Generation of a GDE Heterozygous Mutation Human Embryonic Stem Cell Line WAe001-A-14 by CRISPR/Cas9 Editing. Stem Cell Research. 2018 Mar;27:38-41

3. Liu H K, Guo D S ,……, Li Y-X*. Testosterone improves the differentiation efficiency of insulin-producing cells from human induced pluripotent stem cells. Plos One. 2017 Jun ;12(6):e0179353

4. Guo D S, Liu H K,……, Li Y X*. Modeling Congenital Hyperinsulinism with ABCC8-Deficient Human Embryonic Stem Cells Generated by CRISPR/Cas9. Sci Rep.2017 Jun;7(1):3156

5. Wilbanks A.M. Fralish GB,……, Li Y-X*, Caron GM*. beta-arrestin 2 regulates zebrafish development through the hedgehog signaling pathway. Science. 2004 Dec;306(5705):2264-2267